TSHA - Taysha Gene Therapies, Inc. -  [ ]

Ticker Details
Taysha Gene Therapies, Inc.
IPO Date: September 24, 2020
Sector: Healthcare
Industry: Biotech
Market Cap: $1.58B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.27 | 4.11%
Avg Daily Range (30 D): $0.22 | 3.88%
Avg Daily Range (90 D): $0.16 | 3.17%
Institutional Daily Volume
Avg Daily Volume: 1.7M
Avg Daily Volume (30 D): 2.22M
Avg Daily Volume (90 D): 2.22M
Trade Size
Avg Trade Size (Sh.): 200
Avg Trade Size (Sh.) (30 D): 109
Avg Trade Size (Sh.) (90 D): 123
Institutional Trades
Total Institutional Trades: 671
Avg Institutional Trade: $1.91M
Avg Institutional Trade (30 D): $2.11M
Avg Institutional Trade (90 D): $1.84M
Avg Institutional Trade Volume: .52M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.37M
Avg Closing Trade (30 D): $2.58M
Avg Closing Trade (90 D): $2.11M
Avg Closing Volume: 578.58K
 
News
Apr 29, 2026 @ 12:00 PM
Taysha Gene Therapies to Release First Quarter 202...
Source: Not Specified
Apr 3, 2026 @ 12:00 PM
Taysha Gene Therapies Announces Inducement Grant U...
Source: Na
Mar 19, 2026 @ 12:00 PM
Taysha Gene Therapies Reports Full-Year 2025 Finan...
Source: Not Specified
Feb 6, 2026 @ 1:00 PM
Taysha Gene Therapies Announces Inducement Grant U...
Source: Na
Oct 17, 2025 @ 1:00 PM
Sandhoff Disease Treatment Market Size Projects US...
Source: Towards Healthcare
Financials
  TTM Q1 2026 Q4 2025
Basic EPS $-.38 $-.12 $-.08
Diluted EPS $-.38 $-.12 $-.08
Revenue $7.47M $M $5.49M
Gross Profit
Net Income / Loss $-129.88M $-42.41M $-27.85M
Operating Income / Loss $-132.56M $-43.49M $-28.3M
Cost of Revenue
Net Cash Flow $160.15M $-43.19M $22.59M
PE Ratio